FDA fast-tracks psychedelics

The U.S. Food and Drug Administration has announced it will offer ultra-fast review to three psychedelic drugs intended to treat severe mental health conditions.

The move follows an executive order from President Trump aimed at accelerating access to experimental treatments for depression and PTSD. The fast-track process will apply to compounds being developed for treatment-resistant depression and major depressive disorder.

This shift marks a significant change in federal drug policy, coinciding with the administration's move to reschedule medical marijuana.